Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) shares fell 8.2% on Thursday following a dissappointing earnings announcement. The company traded as low as $44.21 and last traded at $46.38. 145,003 shares changed hands during mid-day trading, a decline of 72% from the average session volume of 516,255 shares. The stock had previously closed at $50.52.
The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The business had revenue of $99.41 million during the quarter, compared to the consensus estimate of $96.64 million.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on MIRM shares. HC Wainwright raised their price target on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a "buy" rating in a report on Friday. Citigroup boosted their target price on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Finally, Robert W. Baird raised their price objective on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a research note on Thursday. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $58.20.
View Our Latest Analysis on MIRM
Insider Activity
In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 9,102 shares of the firm's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $48.22, for a total transaction of $438,898.44. Following the completion of the sale, the chief executive officer now owns 115,920 shares of the company's stock, valued at $5,589,662.40. This trade represents a 7.28 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Peter Radovich sold 1,998 shares of the firm's stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $85,554.36. Following the sale, the chief operating officer now owns 27,015 shares of the company's stock, valued at approximately $1,156,782.30. This represents a 6.89 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 40,915 shares of company stock valued at $1,897,920. 22.87% of the stock is owned by insiders.
Institutional Trading of Mirum Pharmaceuticals
Several institutional investors have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new stake in shares of Mirum Pharmaceuticals during the fourth quarter worth $42,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Mirum Pharmaceuticals by 16.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 73,888 shares of the company's stock worth $3,055,000 after acquiring an additional 10,427 shares during the period. Woodline Partners LP raised its stake in Mirum Pharmaceuticals by 22.2% in the 4th quarter. Woodline Partners LP now owns 404,404 shares of the company's stock worth $16,722,000 after purchasing an additional 73,399 shares in the last quarter. Squarepoint Ops LLC bought a new stake in Mirum Pharmaceuticals in the 4th quarter valued at about $897,000. Finally, Tema Etfs LLC acquired a new position in shares of Mirum Pharmaceuticals during the 4th quarter worth approximately $1,735,000.
Mirum Pharmaceuticals Price Performance
The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. The company's fifty day moving average price is $46.96 and its 200 day moving average price is $43.40. The company has a market capitalization of $2.25 billion, a P/E ratio of -22.77 and a beta of 0.96.
About Mirum Pharmaceuticals
(
Get Free Report)
Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Featured Stories
Before you consider Mirum Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mirum Pharmaceuticals wasn't on the list.
While Mirum Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
